Publications by the TARGET Program
Acute Lymphoblastic Leukemia (ALL)
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
N Engl J Med. 2009 Jan 29;360(5):470-80. doi: 10.1056/NEJMoa0808253
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Proc Natl Acad Sci USA. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia
Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
Blood. 2010 Jul 1;115(26):5312-21. doi: 10.1182/blood-2009-09-245944
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome
Blood. 2010 Dec 2;116(23):4874-84. doi: 10.1182/blood-2009-08-239681
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
Nat Genet. 2011 Mar;43(3):237-41. doi: 10.1038/ng.763.
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood. 2011 Sep 15;118(11):3080-7. doi: 10.1182/blood-2011-03-341412.
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
Blood. 2013 Jan 17;121(3):485-8. doi: 10.1182/blood-2012-04-422691.
The molecular genetic makeup of acute lymphoblastic leukemia
Hematology Am Soc Hematol Educ Program. 2012;2012:389-96. doi: 10.1182/asheducation-2012.1.389.
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
Nat Commun. 2015 Mar 19;6:6604. doi: 10.1038/ncomms7604.
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909.
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0.
The genomic landscape of pediatric acute lymphoblastic leukemia
Nat Genet. 2022 Sep 1. doi: 10.1038/s41588-022-01159-z
Acute Myeloid Leukemia (AML)
Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse
Cancer Res. 2016 Apr 15;76(8):2197-205. doi: 10.1158/0008-5472.CAN-15-1015.
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML
Blood. 2016 Jun 16;127(24):3094-8. doi: 10.1182/blood-2016-04-709899.
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
J Clin Oncol. 2017 Dec 10;35(35):3964-3977. doi: 10.1200/JCO.2017.74.7451.
Genomics in childhood acute myeloid leukemia comes of age
Nat Med. 2018 Jan 9;24(1):7-9. doi: 10.1038/nm.4469.
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439.
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
Leukemia. 2019 Aug;33(8):1934-1943. doi: 10.1038/s41375-019-0402-3.
Predicting Complete Remission of Acute Myeloid Leukemia: Machine Learning Applied to Gene Expression
Cancer Inform. 2019 Mar 15;18:1176935119835544. doi: 10.1177/1176935119835544.
Altered Transcriptome in Pediatric AML Compared with Normal Hematopoiesis
Br J Cancer Res. 2020 Jun 4;3(3):415-422. doi: 10.31488/bjcr.154
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
Nat Commun. 2022 Sep 19;13(1):5487. doi: 10.1038/s41467-022-33244-6
Kidney Tumors – Wilms Tumor (WT)
Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors
Cancer Cell. 2015 Feb 9;27(2):286-97. doi: 10.1016/j.ccell.2015.01.003.
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours
Nat Commun. 2015 Dec 4;6:10013. doi: 10.1038/ncomms10013.
Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
Clin Cancer Res. 2016 Nov 15;22(22):5582-5591. doi: 10.1158/1078-0432.CCR-16-0985.
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
Nat Genet. 2017 Oct;49(10):1487-1494. doi: 10.1038/ng.3940.
A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study
PLoS One. 2018 Dec 13;13(12):e0208936. doi: 10.1371/journal.pone.0208936.
Kidney Tumors – Clear Cell Sarcoma (CCSK)
TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney
Oncotarget. 2015 Jun 30;6(18):15828-41. doi: 10.18632/oncotarget.4682.
Kidney Tumors – Rhabdoid Tumor (RT)
Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways
Cancer Cell. 2016 Mar 14;29(3):394-406. doi: 10.1016/j.ccell.2016.02.009.
Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration
Cell Rep. 2019 Nov 19;29(8):2338-2354.e7. doi: 10.1016/j.celrep.2019.10.013.
Neuroblastoma (NBL)
The genetic landscape of high-risk neuroblastoma
Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529.
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333.
Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism
Nature. 2015 Dec 17;528(7582):418-21. doi: 10.1038/nature15540.
Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
Cancer Discov. 2018 May;8(5):582-599. doi: 10.1158/2159-8290.CD-16-0861.
Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma
Oncogene. 2018 Oct;37(40):5451-5465. doi: 10.1038/s41388-018-0326-9.
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Clin Cancer Res. 2018 Nov 15;24(22):5673-5684. doi: 10.1158/1078-0432.CCR-18-0599.
Osteosarcoma (OS)
Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma
Oncotarget. 2017 May 27;8(57):96738-96752. doi: 10.18632/oncotarget.18236.
Meta-Analyses
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421.
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Nature. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795.
Pan-Cancer Model Systems (MDLS)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.